Since they bottomed in October 2022, the main stock indices have skyrocketed, The S&P 500 recording back-to-back gains of over 20% in 2023-2024, and the tech/growth-oriented Nasdaq-100 has performed even better.They lead the investing group Wheel of Fortune where they share actionable trading ideas across all asset-classes, sectors and industries. The goal of the service is to provide a one-stop-shop for investment and portfolio ideas, while educating the vibrant community of subscribers. Features of the se ...

Day One Biopharmaceuticals (NASDAQ: DAWN ) is a commercial-stage biotech focused on the development and marketing of mostly one drug: an RAF kinase inhibitor indicated for children with certain forms of brain cancer. The company has vacillated between $1 and $2 billion inI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you d ...

Company Overview - Day One Biopharmaceuticals is a biopharmaceutical company focused on developing and commercializing targeted therapies for life-threatening diseases across all age groups [1] - The company was founded to address the critical unmet need in pediatric cancer therapeutic development [3] - Day One aims to re-envision cancer drug development and redefine treatment possibilities for all cancer patients, inspired by "The Day One Talk" between physicians and patients [3] Pipeline and Partnerships - The company's pipeline includes tovorafenib (OJEMDA™), DAY301, and a VRK1 inhibitor program [4] - Day One collaborates with leading clinical oncologists, families, and scientists to identify, acquire, and develop targeted cancer treatments [4] Upcoming Event - Dr Jeremy Bender, CEO of Day One Biopharmaceuticals, will present at the 43rd Annual J P Morgan Healthcare Conference on January 13, 2025, at 3:45 PM Pacific Time / 6:45 PM Eastern Time [1] - A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for 30 days post-presentation [2] Corporate Information - Day One Biopharmaceuticals is headquartered in Brisbane, California [4] - The company utilizes its Investor Relations website, X handle, and LinkedIn page for disseminating business and financial information, including news, announcements, and regulatory disclosures [5]

Dr. Blackman’s departure planned for end of 2024 Company’s search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring ef ...

BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 3:00 p.m. EST. A live webcast of the discussion will be available by visiting the Event ...

Shares of Day One Biopharmaceuticals, Inc. (DAWN) have gained 10.7% over the past four weeks to close the last trading session at $15.15, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.88 indicates a potential upside of 136.8%.The average comprises eight short-term price targets ranging from a low of $28 to a high of $44, with a standard deviation of $5.19. While the lowest ...

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Samuel Blackman - Co-Founder and Head, R&D Charles York - COO and CFO Conference Call Participants Anupam Rama - JPMorgan Joe Catanzaro - Piper Sandler Andrea Newkirk - Goldman Sachs Soumit Roy - Jones Research Alec Stranahan - Bank of America Ami Fadia - Needham & Company Andres Maldonado - H.C. Wainwri ...

Day One Biopharmaceuticals, Inc. (DAWN) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 290%. A quarter ago, it was expected that this company would post a loss of $0.67 per share when it actually produced a loss of $0.05, delivering a surprise of 92.54%.Over the last four quart ...

f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40431 DAY ONE BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2415215 (State ...

Exhibit 99.1 Day One Reports Third Quarter 2024 Financial Results and Corporate Progress Achieved $20.1 million in OJEMDA TM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, October 30, 4:30 p.m. Eastern Time BRISBANE, Calif., Oct. 30, 2024 – Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and co ...